Recent news on Rebif

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year ...  -  May 8, 2007
Oxfordshire Bioscience Network (press release),Treatment with Rebif in the control arm continued without interruption. Alemtuzumab re-dosing in the trial remains on clinical hold in the United States,

Studies Presented At Neurology Conference Highlight Early Efficacy ...  -  May 4, 2007
Medical News Today (press release),The results of a third study, known as BRIGHT (Betaseron versus Rebif(R) InvestigatinG Higher Tolerability),(5) showed that significantly more of the 306

Studies Presented at Neurology Conference Highlight Early Efficacy ...  -  May 3, 2007
PR Newswire (press release),Fewer patients treated with Betaseron versus Rebif reported injection-site reactions. Moreover, with autoinjectors being used by more than 92 percent of

Merck KGaA Has Loss on Serono Costs, Liquid Crystals (Update6)  -  Apr 25, 2007
BloombergMerck bought Switzerland's Serono, Europe's largest biotechnology, this year to add the Rebif multiple sclerosis treatment and become less dependent on

Market Report -- In Play (GENZ)  -  May 2, 2007
MSN MoneyGenzyme says interim analysis of Phase 2 comparative study showed significant results in favor of alemtuzumab versus Rebif Co and Bayer HealthCare

German Drug Maker Merck Posts 1Q Loss  -  Apr 25, 2007
Forbes,The company's operating profit rose to 321 million euros ($435.98 million) from 288 million euros a year earlier, lifted by demand for Erbitux and Rebif,

Modigene Announces Closing of Merger and $9.6 Million Private ...  -  May 15, 2007
PR Newswire (press release),Rebif(R). Among his other clinical achievements, Dr. Havron developed BioTechnology General Ltd.'s (Rehovot, Israel) commercial hGH, BioTropin(R),

BIO 2007 leaves room for lobbying  -  May 12, 2007
Kansas City Star,Smith eventually began treatment with Rebif, a medication marketed by EMD Serono Inc. and Pfizer Inc. The results were dramatic, she said, adding that she

In A Market Of Injectables, Differences In Convenience Can Greatly ...  -  May 9, 2007
eMaxHealth.com,..."Among the injectables, many patients and thought leaders today prefer subcutaneously delivered therapies (Merck Serono's Rebif, Bayer Healthcare

Germany's Bayer says top drug sales rise in Q1  -  May 8, 2007
ReutersDE: Quote, Profile, Research Rebif and Biogen's (BIIB.O: Quote, Profile, Research Avonex, which had higher sales in certain markets.

Germany's Bayer says top drug sales rise in Q1  -  May 8, 2007
Reuters.uk,DE: Quote, Profile , Research) Rebif and Biogen's (BIIB.O: Quote, Profile , Research) Avonex, which had higher sales in certain markets.

Germany's Bayer says top drug sales rise in Q1  -  May 8, 2007
ReutersDE: Quote, Profile , Research) Rebif and Biogen's (BIIB.O: Quote, Profile , Research) Avonex, which had higher sales in certain markets.

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year ...  -  May 7, 2007
Financial News USA (press release),...the sustained accumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Rebif® (interferon beta-1a).

New Route Opens for Rituxan  -  May 1, 2007
TheStreet.com...might be more effective than the four drugs -- Avonex, Betaseron, Copaxone and Rebif -- now considered the standard of care in treating the disease.

Merck KGaA Has Loss on Serono Costs, Liquid Crystals (Update6)  -  Apr 25, 2007
BloombergMerck bought Switzerland's Serono, Europe's largest biotechnology, this year to add the Rebif multiple sclerosis treatment and become less dependent on

DAX Index Rises, Led by SAP; BASF Jumps on Talk About Takeover  -  Apr 13, 2007
BloombergThe drugmaker's Rebif expanded its lead in the multiple sclerosis market over rival Bayer AG's Betaseron treatment, Citigroup analysts wrote in a note today

MEDICAL AND FITNESS NEWS  -  Apr 14, 2007
Chattanooganow (subscription),And Betaseron, Avonex, Rebif and Copaxone -- medicines most have never heard of -- can provide many MS patients with retention of functions that were

First Pharmacoeconomic Analysis with Long-Term Data Showed ...  -  Apr 11, 2007
PharmaLive.com (press release),...lifetime for COPAXONE(R) was estimated to be 34.7 percent, 16.8 percent and 14.5 percent less than Rebif(R), Betaseron(R) and Avonex(R), respectively.

First Pharmacoeconomic Analysis with Long-Term Data Showed ...  -  Apr 11, 2007
Business Wire (press release),...lifetime for COPAXONE ® was estimated to be 34.7 percent, 16.8 percent and 14.5 percent less than Rebif ® , Betaseron ® and Avonex ® , respectively.

MS Patients Not Receiving Medications To Slow Disease Progression ...  -  Apr 20, 2007
Medical News Today (press release),They are: interferon-1b (sold under the name Betaseron®), interferon-1a (Avonex®), glatiramer acetate (GA or Copaxone®), interferon-1a (Rebif®),

MS patients not receiving medications to slow disease progression  -  Apr 18, 2007
News-Medical.net,They are: interferon-1b (sold under the name Betaseron), interferon-1a (Avonex), glatiramer acetate (GA or Copaxone), interferon-1a (Rebif),

New One-Year Pharmacoeconomic Study Shows Avonex® Is Cost ...  -  Apr 18, 2007
Medical News Today (press release),The MS Benchmarks analysis showed the total costs over one-year to MS patients on interferon beta therapy were: AVONEX, $19896.15; Rebif® (Interferon

Light rain showers  -  Apr 17, 2007
Niagarathisweek.com,For the past five years, Shanahan has been taking Rebif injections, which halts the progression of the disease which attacks the protective myelin covering

Merck Serono SA to Voluntarily Delist and Deregister its Bearer ...  -  Apr 6, 2007
Drug Newswire (press release),It has strong market positions in neurology, with Rebif(R), as well as in metabolism and growth, with Saizen(R), Serostim(R) and Zorbtive(TM).

Society asks government to ‘hop to it’  -  Apr 4, 2007
St. John's Telegram,He said this province provides coverage of therapies used in the treatment of MS, such as Betaseron, Copaxone, Avonex and Rebif for beneficiaries of the

EPG Patient Direct Partners With Merck Serono To Produce Psoriasis ...  -  Mar 29, 2007
Medical News Today (press release),The entity has leading brands serving patients in the areas of Oncology (Erbitux®), Neurology (Rebif®), CardioMetabolic Care (Glucophage®, Concor®),

Merck KGaA Announces Serono Preliminary Figures for 2006  -  Mar 23, 2007
Drug Newswire (press release),Rebif(R) sales were up 14% to $1452 million in 2006 and increased by 16% to $388 million in the fourth quarter. In 2006, Rebif sales in the US gained 26% to

Merck Says Profit at Serono Unit Rose on Rebif Drug (Update3)  -  Mar 1, 2007
Bloomberg...said profit at the Swiss biotechnology company rose in the fourth quarter as doctors prescribed more of the Rebif multiple sclerosis treatment.

Dueling Fools: Elan Bear  -  Mar 15, 2007
Motley FoolSecond, Elan has gotten the benefit of using Biogen's experienced and large sales force, whereas Avonex and Rebif were launched in much more difficult

Germany's Merck Reports 4Q Profit Jump  -  Mar 1, 2007
Houston Chronicle,Sales were also helped by an increase in demand for the Rebif multiple sclerosis treatment and by strong demand for the Erbitux cancer medicine.

Merck 4Q Earnings Up More Than 18.2 Pct.  -  Mar 1, 2007
Forbes,Sales were also helped by an increase in demand for the Rebif multiple sclerosis treatment and by strong demand for Erbitux. Rebif is made by Swiss biotech

Market Report -- In Play (SRA)  -  Mar 1, 2007
MSN MoneyRebif sales were up 14% to $1452 mln in 2006 and increased by 16% to $388 mln in Q4. In 2006, Rebif sales in the US gained 26% to $493 mln for the full year

Merck KGaA is delighted as Serono earnings soar  -  Mar 1, 2007
Pharma Times (subscription),For the full year, Rebif (interferon beta-1a) sales were up 14% to $1.45 billion, and up 26% in the USA to $493 million, despite increasing competition in

Pfizer's a Sell: Shrinking Top Line, No Blockbusters In the Pipeline  -  Mar 22, 2007
Seeking Alpha,Alliance drugs, such as Rebif for multiple sclerosis and Aricept for Alzheimer's disease, have contributed nicely to the bottom line.

Merck Serono Confirms Previously Announced 2006 Figures  -  Mar 21, 2007
PharmaLive.com (press release),It has strong market positions in neurology, with Rebif(R), as well as in metabolism and growth, with Saizen(R), Serostim(R) and Zorbtive(TM).

An Israeli Biotech Company Plays the Field  -  Mar 13, 2007
BusinessWeekThey include multiple sclerosis drugs Copaxone and Rebif, from Teva and Merck Serono (SRA), respectively; and Doxil, an ovarian cancer drug from Johnson

German Stocks Rise, Paced by Daimler; Deutsche Telekom Declines  -  Mar 1, 2007
Bloomberg...year said profit at the Swiss biotechnology company rose in the fourth quarter as doctors prescribed more of the Rebif multiple sclerosis treatment.

European Stocks Slump May Continue, Led by BP, Deutsche Telekom  -  Feb 28, 2007
BloombergSA this year said profit at the Swiss biotechnology company rose in the fourth quarter as doctors prescribed more of the Rebif multiple sclerosis treatment.

German Merck says FDA seeks more data on Rebif  -  Feb 6, 2007
ReutersDE: Quote, Profile , Research) said on Tuesday a US regulator has asked for more data on a new formulation of its multiple sclerosis drug Rebif,

FDA Has Questions on Merck KGaA's New Rebif, Delaying Approval  -  Feb 6, 2007
BloombergRebif is the second-biggest multiple sclerosis drug behind Biogen Idec Inc.'s Avonex. Merck Serono plans to use the new formulation to increase its share of

One Utahn with MS Experiencing a Miraculous Recovery  -  Feb 19, 2007
KSL-TV,IV steroids and an interferon treatment called REBIF worked for a while, but when they failed, Darren was given what is called the Tysabri therapy.

When time’s the enemy  -  Feb 13, 2007
Fort Wayne Journal Gazette,A common side effect of the first one, Rebif, is depression. “I hated the feeling of being down all the time, but I also didn’t want to take antidepressants

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 30, 2007
Drug Newswire (press release),It has strong market positions in neurology, with Rebif(R), as well as in metabolism and growth, with Saizen(R), Serostim(R) and Zorbtive(TM).

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 29, 2007
Yahoo! News (press release)It has strong market positions in neurology, with Rebif®, as well as in metabolism and growth, with Saizen®, Serostim® and Zorbtive(TM).

Medical Edge: Plasma exchange used as treatment, not cure, for MS  -  Jan 27, 2007
Bryan College Station Eagle,The best known among them are interferon beta-1b (Betaseron) and interferon beta-1a (Avonex, Rebif), which are genetically engineered copies of proteins

Novartis, Merck Profit Rises on Sales of Older Cancer Medicines  -  18 Jan 2007
BloombergNovartis is awaiting approval of cancer and heart treatments and Merck is buying Switzerland's Serono SA to add Rebif for multiple sclerosis.

Merck KGaA Fourth-Quarter Profit Rose 18% on Liquid Crystals  -  18 Jan 2007
BloombergMerck is buying Serono to become Europe's largest biotechnology company and add Rebif, the best-selling multiple sclerosis treatment outside the US The

Merck Serono Completes Patient Enrollment in CLARITY Phase III ...  -  Jan 16, 2007
Drug Newswire (press release),In addition to Rebif(R), the Company also offers a second therapy within its US portfolio of MS therapies: Novantrone(R) (mitoxantrone for injection

Viragen announces that OVA™ System results are published in ...  -  Jan 17, 2007
Checkbiotech.org (press release),Rebif® (interferon beta-1a) is a registered trademark of Serono, Inc. Viragen has no agreements with Biogen Idec or Serono and did not collaborate with

Merck Serono SA starts first official day of operations  -  Jan 8, 2007
International Herald Tribune,Two of its main growth drivers are the cancer drug Erbitux and multiple sclerosis treatment Rebif. Merck now holds 84 percent of the capital and 89 percent

Merck KGaA Might Sell Unit  -  Jan 5, 2007
TheStreet.comMerck offered $13.3 billion in September for the company whose major product is the multiple sclerosis drug Rebif. All told, it now hold 84% of Serono's

Cancer Curing Omelets?  -  Jan 15, 2007
Red Herring,There are two principal competitors in the market for the MS drug, Biogen Idec’s Avonex, and Serono’s Rebif, which according to Viragen see over $2.5

Merck Serono is Launched  -  Jan 8, 2007
Drug Newswire (press release),It has strong market positions in neurology, with Rebif(R), as well as in metabolism and growth, with Saizen(R), Serostim(R) and Zorbtive(TM).

Merck Serono is Launched  -  Jan 7, 2007
Yahoo! News (press release)It has strong market positions in neurology, with Rebif®, as well as in metabolism and growth, with Saizen®, Serostim® and Zorbtive(TM).

Merck KGaA Considers Sale of Generics Medicines Unit (Update7)  -  Jan 5, 2007
BloombergBy buying Geneva-based Serono, Merck will gain Rebif, the best-selling MS medicine outside the US, as well as infertility treatments such as Gonal-F.

Texas Pacific, Cinven, Permira May Bid for Merck Unit (Update3)  -  Jan 11, 2007
BloombergMerck may exit the business to focus on more profitable branded drugs after last year bidding $13.5 billion for Serono SA and Rebif for multiple sclerosis.

Generics unit may be sold as Merck Serono is launched  -  Jan 8, 2007
Pharma Times (subscription),...euros and "the two key growth drivers," the colorectal cancer drug Erbitux (cetuximab) and the multiple sclerosis treatment Rebif (interferon beta-1a).

Serono: Merck Closes Share-Purchase Deal  -  Jan 5, 2007
Houston Chronicle,Concor and cancer drug Erbitux, access to new markets thanks to Serono's partnership with Pfizer Inc. to market the multiple sclerosis drug Rebif.

Merck KGaA Acquires Majority Shareholding in Serono SA  -  Jan 5, 2007
Genetic Engineering News (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and

Merck KGaA Acquires Majority Shareholding in Serono SA  -  Jan 5, 2007
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®.

For kids, MS itself just half the battle  -  Jan 6, 2007
Contra Costa Times,..."It makes you feel so uncertain and so afraid," said the soft-spoken girl, who started three-times-a-week injections of the drug Rebif in November.

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),...were released in September and showed a robust, statistically significant treatment effect for alemtuzumab compared with Rebif® (interferon beta-1a).

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Drug Newswire (press release),...were released in September and showed a robust, statistically significant treatment effect for alemtuzumab compared with Rebif(R) (interferon beta-1a).

Pfizer's new antismoking pill may be a hard sell  -  Dec 26, 2006
Naples Daily News,Pfizer also offers online support and phone help for patients taking Sutent, a pill for kidney cancer, and Rebif, a multiple sclerosis treatment.

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R)

Pfizer's new antismoking pill may be a hard sell  -  26 Dec 2006
Naples Daily News,Pfizer also offers online support and phone help for patients taking Sutent, a pill for kidney cancer, and Rebif, a multiple sclerosis treatment.

Serono launches Rebif Phase III trials in patients at risk of ...  -  Dec 11, 2006
Forbes,...of two dosage regimens of its new formulation of blockbuster multiple sclerosis (MS) treatment Rebif in patients at risk of developing the disease.

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  Dec 12, 2006
Drug Newswire (press release),The trial, called the REFLEX study (REbif FLEXible dosing in early MS), will involve 480 patients considered at risk of developing MS because of a recently

Market Report -- In Play (SRA)  -  Dec 12, 2006
MSN MoneySerono announces initiation of the Reflex trial to evaluate new formulation of Rebif in patients at risk of developing MS Co announces the initiation of a

Schering's Campath reports promising first-line Ph III data  -  Dec 12, 2006
Pharma Times (subscription),Furthermore, Campath is given just once a year, while Rebif is administered three times a week, providing another significant treatment advantage.

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R)

Multiple Sclerosis Is the Most Common Cause of Neurological ...  -  Dec 19, 2006
PharmaLive.com (press release),Avonex (Biogen Idec), Betaseron/Betaferon (Schering AG), Copaxone (Teva), Novatrone (Schering AG), Rebif (Serono/Pfizer) and Tysabri (Biogen Idec/Elan).

Merck Cleared to Buy Stake in Serono  -  Dec 18, 2006
Houston Chronicle,Concor and cancer drug Erbitux, access to new markets thanks to Serono's partnership with Pfizer Inc. to market the multiple sclerosis drug Rebif.

Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono  -  Dec 17, 2006
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel ®/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®.

Study shows treatment should begin with first MS attack  -  Dec 16, 2006
Jerusalem Post,Early intervention, he said, would probably work for Teva's Copaxone and Biogen's Avonex or Serono's Rebif (both interferon beta 1-a), and not only for

Swiss shares close higher led by UBS, Roche UPDATE  -  Dec 12, 2006
Forbes,...a new Phase III clinical trial to evaluate the effect of a new formulation of key MS treatment Rebif in patients at risk of developing the disease.

(PRN) - Central European Telecommunications Provider Selects Sonus ...  -  Dec 12, 2006
Bolsamania.com,...(PRN) - Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis ... [+]

(PRN) - Central European Telecommunications Provider Selects Sonus ...  -  Dec 12, 2006
Bolsamania.com,...(PRN) - Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis ... [+]

Analysts React to Pfizer Setback  -  Dec 4, 2006
Wall Street Journal (subscription),Furthermore, recent acquisitions (Pharmacia and Vicuron) and partnerships (Eyetech's Macugen [now OSI Pharmaceuticals] and Serono's Rebif) have added little

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)Reduced immunogenicity with a new formulation of interferon-beta-1a (Rebif): 24-week results of a phase IIIb study. Program and abstracts of the 22nd

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional